Opinion
Video
Author(s):
Expert oncologists explore emerging therapies being investigated in CLL, including BTKi degraders, CAR-T therapy, and bispecific antibodies, and discussed their potential impact in shaping the future of CLL treatment.
Pembrolizumab Plus B-Cell Receptor Inhibitors Generates Responses in Richter Transformation of CLL/SLL
Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer
Autologous TIL Therapy Plus Pembrolizumab Under Exploration in PD-L1–Resistant Advanced HNSCC
Revisit the OncLive On Air Episodes From February 2024
Pelabresib/Ruxolitinib Data Underscore Need for Novel End Points in Myelofibrosis Trials
First-Line Orelabrutinib Plus FCG Generates Rapid Molecule Remissions in CLL
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC
Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC
Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer
Research Propels Additional Options into the Advanced HER2+ Breast Cancer Armamentarium